Takeda to distribute Y-mAbs' cancer antibody treatment in Israel

By The Science Advisory Board staff writers

December 4, 2020 -- Y-mAbs and Takeda Israel, a subsidiary of Takeda Pharmaceutical, have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of naxitamab-gqgk (Danyelza) and omburtamab.

Danyelz was approved by the U.S. Food and Drug Administration (FDA) on November 25, for the treatment of with relapsed/refractory high-risk neuroblastoma. Y-mAbs plans to resubmit an amended biologics license application for omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or early in 2021. Omburtamab targets tumors that express B7-H3.

Under the agreement, Takeda will be responsible for the sales, access, marketing, and regulatory activities to distribute Danyelza and omburtamab in the territory (State of Israel, West Bank, and Gaza Strip). All other geographies worldwide remain with Y-mAbs.

Financial details of the agreement were not disclosed.

Regulatory Roundup: antibodies, immunotherapies, expanded flu treatment use
Welcome to this week's edition of Regulatory Roundup. This past week, several novel therapies for the treatment of rare diseases and cancers have received...

Copyright © 2020 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter